Cross-Sectional Study Links Lower Whole-Blood NAD+ Levels to Frailty in Older Adults
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
A cross-sectional analysis of 529 older Japanese adults indicates that higher whole-blood NAD+ concentrations are associated with lower odds of frailty, though the relationship appears partly mediated by blood cell composition.
What happened
Researchers analyzed cross-sectional data from 529 community-dwelling older adults aged 65 years and older from the 2025 Itabashi Longitudinal Study on Aging.
Frailty was identified in 32 participants (6.0% of the cohort) based on the revised Japanese Cardiovascular Health Study Criteria.
The median whole-blood NAD+ concentration was significantly lower in frail participants compared to non-frail participants (24.00 µmol/L vs. 25.00 µmol/L; P = 0.007).
After adjusting for age, sex, and fasting time, a 1 µmol/L increase in whole-blood NAD+ concentration was associated with lower odds of frailty (OR 0.871; 95% CI, 0.780–0.970; P = 0.013).
Further adjustment for hematocrit attenuated the association (OR 0.911; 95% CI, 0.800–1.034), indicating that blood cell composition may explain a portion of this correlation.
Why it matters
While preclinical studies have firmly linked NAD+ depletion to metabolic and physiological decline, human epidemiological data connecting circulating NAD+ levels directly to frailty phenotypes has been sparse.
The attenuation of the association upon hematocrit adjustment reveals a key methodological limitation: whole-blood NAD+ metrics may reflect hematological variables, such as red blood cell volume, rather than systemic cellular energy depletion.
The findings suggest that therapeutic trials and diagnostics evaluating NAD+ replenishment may require more localized, cell- or tissue-specific assays to properly establish efficacy and mechanistic relationships with physical frailty.
Market impact
This study introduces a cautionary note for the longevity sector's diagnostic and therapeutic companies relying on whole-blood measurements to validate the efficacy of NAD+-boosting compounds.
Assay developers and biomarker platforms may see increased demand for advanced, cell-fractionated, or tissue-specific NAD+ quantification technologies rather than simple whole-blood or fingerstick tests.
What comes next
Further clinical validation trials and longitudinal studies that utilize cell- and tissue-specific NAD+ measurements to clarify the causal relationship between NAD+ metabolism, hematological parameters, and frailty progression.
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH